# Paclitaxel-Avelumab for Angiosarcoma

> **NCT03512834** · PHASE2 · UNKNOWN · sponsor: **Sung Yong Oh** · enrollment: 32 (estimated)

## Conditions studied

- Angiosarcoma Metastatic

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03512834
- **Lead sponsor:** Sung Yong Oh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-01
- **Primary completion:** 2022-11
- **Final completion:** 2023-05
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2018-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03512834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03512834, "Paclitaxel-Avelumab for Angiosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03512834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*